The KC increase was significantly lower in the treated groups compared to the BD group: Coversin group 502 pg/mL (356–658) (p = 0.004), anti-CD14 group 666 pg/mL (185–1147) (p = 0.006) and the dual treatment group 744 pg/mL (511–977) (p = 0.006) (Fig. 1B). Here, CALCA is linked to Behcet disease.